Disease details

臨床試験数 : 29 / 薬物数 : 25 - (DrugBank : 11) / 標的遺伝子数 : 4 - 標的パスウェイ数 : 20

9 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04045834 (ClinicalTrials.gov)	May 5, 2019	4/8/2019	Study of the Diagnostic Value of Hybrid PET/MR and PET/CT in Neuroendocrine Diseases and Tumor Induced Osteomalacia	Study of the Diagnostic Value of Hybrid PET/MR and PET/CT in Neuroendocrine Diseases and Tumor Induced Osteomalacia	PET / CT;PET / MR;Neuroendocrine Tumors;Osteomalacia	Device: 68Ga-DOTA-TATE PET/MR and PET/CT imaging	Wuhan Union Hospital, China	NULL	Recruiting	20 Years	80 Years	All	60		China
2	NCT03510455 (ClinicalTrials.gov)	February 27, 2019	26/4/2018	BGJ398 for the Treatment of Tumor-Induced Osteomalacia	BGJ398 for the Treatment of Tumor-Induced Osteomalacia	Tumor-Induced Osteomalacia;Oncogenic Osteomalacia	Drug: BGJ398	National Institute of Dental and Craniofacial Research (NIDCR)	NULL	Completed	18 Years	85 Years	All	4	Phase 2	United States
3	NCT03736564 (ClinicalTrials.gov)	January 31, 2019	30/10/2018	Ga-DOTATATE PET for Phosphaturic Mesenchymal Tumors in Patients With Tumor Induced Osteomalacia	68Ga-DOTATATE PET for Localization of Phosphaturic Mesenchymal Tumors in Patients With Tumor Induced Osteomalacia	Osteomalacia	Combination Product: 68Ga-DOTATATE PET/CT	Mayo Clinic	NULL	Recruiting	18 Years	N/A	All	10	Phase 1/Phase 2	United States
4	NCT03775187 (ClinicalTrials.gov)	January 4, 2018	11/12/2018	Expanded Access to Burosumab		X-linked Hypophosphatemia;Tumor-Induced Osteomalacia	Biological: Burosumab	Ultragenyx Pharmaceutical Inc	Kyowa Kirin Co., Ltd.	Available	N/A	N/A	All			NULL
5	NCT02722798 (ClinicalTrials.gov)	April 2016	7/3/2016	A Study of KRN23 in Subjects With Tumor-Induced Osteomalacia or Epidermal Nevus Syndrome	A Phase 2 Open-Label Trial to Assess the Efficacy and Safety of KRN23 in Patients With Tumor-Induced Osteomalacia or Epidermal Nevus Syndrome	Tumor-Induced Osteomalacia or Epidermal Nevus Syndrome	Drug: KRN23	Kyowa Kirin Co., Ltd.	NULL	Active, not recruiting	18 Years	N/A	All	6	Phase 2	Japan;Korea, Republic of
6	JPRN-JapicCTI-163191	23/4/2015	08/03/2016	A Phase 2 Open-Label Trial of KRN23	A Phase 2 Open-Label Trial to Assess the Efficacy and Safety of KRN23 in Patients with Tumor-Induced Osteomalacia or Epidermal Nevus Syndrome	Tumor-Induced Osteomalacia or Epidermal Nevus Syndrome	Intervention name : KRN23 INN of the intervention : burosumab Dosage And administration of the intervention : repeated SC administration, intraindividual dose adjustment Control intervention name : - INN of the control intervention : - Dosage And administration of the control intervention : -	Kyowa Kirin Co., Ltd.	NULL	complete	18		BOTH	6	Phase 2	Japan, Asia except Japan
7	NCT02304367 (ClinicalTrials.gov)	March 24, 2015	24/11/2014	Study of Burosumab (KRN23) in Adults With Tumor-Induced Osteomalacia (TIO) or Epidermal Nevus Syndrome (ENS)	A Phase 2 Open-Label Trial to Assess the Efficacy and Safety of KRN23, an Antibody to FGF23, in Subjects With Tumor-Induced Osteomalacia (TIO) or Epidermal Nevus Syndrome (ENS)-Associated Osteomalacia	Tumor Induced Osteomalacia (TIO);Epidermal Nevus Syndrome (ENS)	Biological: Burosumab	Ultragenyx Pharmaceutical Inc	NULL	Active, not recruiting	18 Years	N/A	All	17	Phase 2	United States
8	NCT01748812 (ClinicalTrials.gov)	November 16, 2012	11/12/2012	Cinacalcet for Fibroblast Growth Factor 23 (FGF23)-Mediated Hypophosphatemia (Hypophosphatemic Rickets)	Open-label Dose-titration Study of the Tolerability and Efficacy of Cinacalcet to Treat Fibroblast Growth Factor 23 (FGF23)-Mediated Hypophosphatemia	Osteomalacia	Drug: Osteomalacia	National Institute of Dental and Craniofacial Research (NIDCR)	NULL	Terminated	18 Years	70 Years	All	1	Phase 1	United States
9	ChiCTR-OOC-16010095	2006-01-01	2016-12-07	Oral Phosphate Supplements Play an Important Role in Improving the Bone Mineral Density of Hypophosphatemic Osteomalacia Patients	Effect of Phosphate on hypophosphatemia	Hypophosphatemic Osteomalacia	A1:received phosphate solution doses at a frequency dependent upon measured serum phosphorus levels;A2:received phosphate solution doses only every three to four days;A3:received no phosphate solution;A:Hypophosphatemic Osteomalacia;B:Control;	The Second Xiangya Hospital, Central South University	NULL	Completed			Both	A1:3;A2:5;A3:3;A:21;B:105;		China

先頭へ